Natco Pharma gets DCGI nod to sell hepatitis C treatment drug

Drug major Natco Pharma has got approval from the Drugs Controller General of India (DCGI) to sell generic version of Daclatasvir, which is used for treatment of chronic hepatitis C.
In a BSE filing today, Natco Pharma said: "It is the first company in India to get approval for generic Daclatasvir Dihydrochloride (Daclatasvir) tablets, 30 mg & 60 mg, from the Drugs Controller General (India)."
Daclatasvir is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection.
"Compared with other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets," the company said.

Natco said it will market generic Daclatasvir under its own brand 'NATDAC', and through its strategic partners in India.
Natco will launch immediately in India at Rs 6,000 and Rs 4,000 for the 60 mg and 30 mg strengths, respectively, for a bottle of 28 tablets.